Journal of BUON
·
2020
·Vol. 25
·期 2
·681-687
·
IF 1.695
Han X,Wang Z
Purpose This study aimed to investigate the efficacy of albumin-bound paclitaxel (nab-paclitaxel) in the treatment of advanced refractory breast cancer (BC) and its effect on serum resistin. Methods A retrospective study was performed based on the clinical records of 95 patients with advanced refractory BC admitted to Weihai Central Hospital from March 2012 to May 2015. Thirty-four patients were treated with traditional paclitaxel and enrolled in the control group, while the other 61 patients were treated with nab-paclitaxel and enrolled in the study group. The efficacy, toxicity and side effects, quality of life, and serum resistin levels were compared between the two groups. Results The total response rate (RR) of the study group was much higher than that of the control group (p<0.05). The leukopenia level of the study group during the treatment was significantly lower than that of the control group (p<0.05). The level of serum resistin in the study group after treatment was significantly lower than in the control group (p<0.05). The improvement rate of quality of life in the study group was significantly higher than in the control group (p<0.05). Conclusion The results indicated that nab-paclitaxel is very effective in treating advanced refractory BC and reduces the level of serum resistin. It can improve the quality of life of patients and is worthy of clinical promotion.
研究领域:
肿瘤学
·
药理学
·
癌症研究
✓ 已验证
DOI
PubMed
高影响因子
Frontiers in Medicine
·
2022
·
IF 5.058
Lifang Ye,Yu Zuo,Fang Chen,Yuetong Xu,Puli Zhang,Hongxia Yang,Sang Lin,Qinglin Peng,Guochun Wang,Xiaoming Shu
Objective In the current study, we aimed to assess resistin mRNA levels in the peripheral blood mononuclear cells (PBMCs) of dermatomyositis patients with interstitial lung disease (DM-ILD) and their correlation with disease activity. Methods We detected resistin mRNA levels in the PBMCs of 37 DM-ILD, 8 DM patients without ILD, and 19 healthy control (HC) subjects by performing quantitative reverse transcription real-time polymerase chain reaction analysis. Associations between resistin expression levels and major clinical manifestations, laboratory examinations, and disease activity were also analyzed. In addition, resistin expression in lung specimens from patients with DM-ILD was examined via immunohistochemistry and immunofluorescence. Results Resistin mRNA levels in PBMCs were significantly higher in DM-ILD than that in DM patients without ILD and HCs ( p = 0.043, 0.014, respectively). Among these DM-ILD patients, the resistin levels were significantly elevated in those with rapidly progressive ILD than in those with chronic ILD ( p = 0.012). The resistin mRNA levels in DM-ILD positively correlated with serum alanine aminotransferase (r = 0.476, p = 0.003), aspartate aminotransferase (r = 0.488, p = 0.002), lactate dehydrogenase (r = 0.397, p = 0.014), C-reactive protein (r = 0.423, p = 0.008), ferritin (r = 0.468, p = 0.003), carcinoembryonic antigen (r = 0.416, p = 0.011), carbohydrate antigen 125 (r = 0.332, p = 0.047), interleukin-18 (r = 0.600, p < 0.001), and lung visual analog scale values (r = 0.326, p = 0.048), but negatively correlated with the diffusing capacity of carbon monoxide (DLco)% (r = −0.447, p = 0.041). Immunohistochemical analysis of resistin showed its elevated expression in the macrophages, alveolar epithelial cells, and weak fibrotic lesions from patients with DM-ILD. Immunofluorescence staining confirmed CD68+ macrophages co-express resistin. Conclusions Resistin levels were increased in patients with DM-ILD and associated with disease activity and ILD severity. Therefore, resistin may participate in the pathogenesis of DM-ILD and may act as a useful biomarker.
研究领域:
风湿病学
·
呼吸病学
·
免疫学
·
分子生物学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）